Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BIIB - Biogen Inc


IEX Last Trade
204.63
-0.190   -0.093%

Share volume: 878,984
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$204.82
-0.19
-0.09%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
36%
Profitability 38%
Dept financing 13%
Liquidity 24%
Performance 43%
Company vs Stock growth
vs
Performance
5 Days
-0.12%
1 Month
-3.36%
3 Months
-6.96%
6 Months
-7.66%
1 Year
-23.36%
2 Year
4.43%
Key data
Stock price
$204.63
P/E Ratio 
25.74
DAY RANGE
$202.84 - $206.19
EPS 
$7.94
52 WEEK RANGE
$189.44 - $270.50
52 WEEK CHANGE
-$0.23
MARKET CAP 
29.826 B
YIELD 
N/A
SHARES OUTSTANDING 
145.662 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
0.71
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$714,167
AVERAGE 30 VOLUME 
$846,029
Company detail
CEO: George Scangos
Region: US
Website: https://www.biogen.com/
Employees: 13,414
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili

Recent news